The Stowers Institute’s Baumann Lab has identified the long-sought telomerase RNA gene in a single-cell research model. Their findings have been posted to the Web site of the journal Nature Structural & Molecular Biology and will appear in a future print edition.
Chromosomes shorten with every cell division. In stem cells and in cancer cells, this shortening is compensated by telomerase, an enzyme that adds short repeat sequences to the ends of chromosomes to replenish lost DNA. As telomerase is required for the continued growth of most cancer cells, the enzyme is considered a promising target for new anti-cancer drugs. A correlation between telomere length and a variety of diseases has further intensified interest in understanding telomerase and its regulation.
The RNA subunit of telomerase is of particular interest as it represents one of the two core components of telomerase and provides the template for the short repeats that are added to the ends of chromosomes. The Baumann Lab is working to understand how telomerase is assembled, how it is recruited to chromosome ends, and how its activity is regulated. These efforts may shed light on the sometimes surprising correlations between telomere shortening and stress, smoking, obesity, and a variety of diseases including cancer and coronary heart disease.
Telomerase RNA has been studied in a variety of simple model organisms, but telomere maintenance turned out to be quite different in these species compared to human cells. Recently, the Baumann Lab used a biochemical approach to identify and clone the RNA subunit of telomerase in Schizosaccharomyces pombe, or fission yeast.
“The identification of the fission yeast equivalent of the telomerase RNA gene provides us with a critical tool to study telomerase in a genetically tractable, single-cell organism with a telomere maintenance machinery that shares many features with human cells,” explained Peter Baumann, Ph.D., Assistant Investigator and senior author on the paper. “We and others had been studying telomerase activity, recruitment, and regulation for several years but the fact that the RNA subunit was unknown in our fission yeast model system severely limited our ability to make progress.”
Now that the missing component of the model system has been identified, the Baumann Lab’s structural and functional studies are expected to progress rapidly. The lab is now turning its attention to how and where telomerase is assembled from its components in the cell and what processing it must undergo to become active.
Source: Stowers Institute for Medical Research
Related stories:
Researchers discover mechanism that explains how cancer enzyme winds up on ends of chromosomes
Human cancer cells divide and conquer. Unless physicians can control that division with surgery, chemotherapy or radiation, the wildly dividing cells will eventually destroy a person's life.
Landmark study opens door to new cancer, aging treatments
Researchers at The Wistar Institute have deciphered the structure of the active region of telomerase, an enzyme that plays a major role in the development of nearly all human cancers. The landmark achievement opens the door to the creation of new, broadly effective cancer drugs, as well as anti-aging therapies.
Keeping cells youthful: How telomere-building proteins get drawn into the fold
It may take just one or two proteins to polish off a simple cellular task, but life-or-death matters, such as caring for the ends of chromosomes known as telomeres, require interacting crews of proteins, all with a common goal but each with a specialized task.
Researchers unmask proteins in telomerase, a substance that enables cancer
One of the more intriguing workhorses of the cell, a protein conglomerate called telomerase, has in its short history been implicated in some critical areas of medicine including cancer, aging and keeping stem cells healthy. With such a resume, telomerase has been the subject of avid interest by basic scientists and pharmaceutical companies alike, so you'd think at the very least people would know what it is.
Telomerase enzyme structure provides significant new target for anti-cancer therapies
Inappropriate activation of a single enzyme, telomerase, is associated with the uncontrollable proliferation of cells seen in as many as 90 percent of all of human cancers. Since the mid-1990s, when telomerase was first identified in human tumors, scientists have eyed the enzyme as an ideal target for developing broadly effective anti-cancer drugs.
Blame our evolutionary risk of cancer on body mass
A key enzyme that cuts short our cellular lifespan in an effort to thwart cancer has now been linked to body mass. Until now, scientists believed that our relatively long lifespans controlled the expression of telomerase--an enzyme that can lengthen the lives of cells, but can also increase the rate of cancer.
Targeted virus compels cancer cells to eat themselves
An engineered virus tracks down and infects the most common and deadly form of brain cancer and then kills tumor cells by forcing them to devour themselves, researchers at The University of Texas M. D. Anderson Cancer Center report this week in the Journal of the National Cancer Institute.
Medicine award kicks off Nobel Prize announcements
(AP) -- Two scientists who have won acclaim for research into the growth of cancer cells could be candidates for the Nobel Prize in medicine when the 2008 winners are presented on Monday, kicking off six days of Nobel announcements.